55 results on '"Adelstein, David J."'
Search Results
2. Single-institute outcomes of palliative chemotherapy in metastatic head and neck squamous cell carcinoma (HNSCC).
3. Combination of tumor multinucleation and spatial arrangement of tumor-infiltrating lymphocytes to predict overall survival in oropharyngeal squamous cell carcinoma: A multisite study.
4. Computerized features of spatial interplay of tumor-infiltrating lymphocytes predict disease recurrence in p16+ oropharyngeal squamous cell carcinoma: A multisite validation study.
5. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion
6. Role of Treatment Deintensification in the Management of p16+ Oropharyngeal Cancer: ASCO Provisional Clinical Opinion Summary
7. Clinical Factors Associated With Cost in Head and Neck Cancer: Implications for a Bundled Payment Model
8. Outcomes of postoperative treatment with concurrent chemoradiotherapy (CRT) in high risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration.
9. Incidence of severe late toxicities of head and neck squamous cell cancer (HNSCC) treatment in the era of intensity modulated radiotherapy (IMRT).
10. Nationwide treatment patterns of oropharyngeal cancer in the human papillomavirus era.
11. Preliminary safety results of a phase II study investigating pembrolizumab in combination with postoperative intensity modulated radiotherapy (IMRT) in resected high risk cutaneous squamous cell cancer of the head and neck.
12. Outcomes of post-operative treatment with concurrent systemic therapy and radiotherapy (RT) in intermediate (INT) risk resected oral cavity squamous cell carcinoma (OCSCC): A multi-institutional collaboration.
13. Reply to A. Piccardo et al, E. Hindié et al, M.C. Kreissl et al, M. Doss, J. Buscombe, R. Fisher, M. Sollini et al, M. Lichtenstein, and M. Tulchinsky et al
14. Risk of Hematologic Malignancies After Radioiodine Treatment of Well-Differentiated Thyroid Cancer
15. The prognostic impact of level I lymph node involvement in oropharyngeal squamous cell carcinoma.
16. Facility volume and head and neck squamous cell carcinoma: Trends and effect on survival.
17. Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
18. Radiation Therapy for Oropharyngeal Squamous Cell Carcinoma: American Society of Clinical Oncology Endorsement of the American Society for Radiation Oncology Evidence-Based Clinical Practice Guideline
19. Prognostic factors associated with benefit to post-operative chemotherapy: A National Cancer Data Base analysis.
20. Do patients learn from survivorship care plans?
21. Outcomes of definitive radiotherapy (dRT) and chemo-radiotherapy (dCRT) for loco-regionally confined (LRC) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ).
22. Association of quality of life (QOL) with oncologic and functional outcomes in head and neck cancer (HNC) patients (pts).
23. Clinical predictive factors of overall survival and locoregional failure in advanced laryngeal cancer treated with definitive chemoradiation.
24. Pathologic and clinical outcomes in cT2N0 esophageal cancer: A cohort study.
25. Measuring impact of survivorship care plans on head and neck cancer patients.
26. The impact of persistent dysphagia (PD) after induction chemotherapy in patients with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ) receiving a tri-modality treatment regimen.
27. Quality of life (QOL) as a predictor of clinical outcome in patients (pts) with head and neck cancer (HNC).
28. Prospective clinical study of precision oncology in solid tumors.
29. The relationship between pathologic nodal disease and residual tumor viability (RV) in patients with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastro-esophageal junction (E/GEJ) receiving induction chemotherapy, surgery, and post-operative chemo-radiotherapy (CRT).
30. Retrospective analysis of benefit from concurrent chemoradiotherapy (CRT) in high-risk squamous cell carcinoma of the oral cavity (SCC-OC).
31. The impact of persistent dysphagia (PD) after induction chemotherapy in patients with locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (E/GEJ) receiving a trimodality treatment regimen.
32. The relationship between pathologic nodal disease and residual tumor viability (RV) in patients with locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus and gastroesophageal junction (E/GEJ) receiving induction chemotherapy, surgery, and postoperative chemoradiotherapy (CRT).
33. Risk factors predictive for poor outcomes in patients with human papillomavirus (HPV)-initiated oropharyngeal cancer (OPC).
34. Inferior local control for T2bN0 glottic carcinoma with impaired mobility treated with radiation alone: A need for more chemotherapy?
35. NCI pilot intervention program to assist accrual for challenging late-phase clinical trials.
36. The impact of 5-fluorouracil (5FU) dose intensity (DI) on survival outcomes in patients (pts) receiving multimodality therapy for locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
37. Induction Chemotherapy Meta-Analysis in Head and Neck Cancer: Right Answer, Wrong Question
38. A phase II trial of induction epirubicin, oxaliplatin, and flourouracil, surgery and post-operative concurrent cisplatin and fluorouracil chemoradiotherapy (CRT) in patients (pts) with loco-regionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
39. A phase III randomized trial of two cisplatin-based concurrent chemoradiation (CCRT) regimens for locally advanced head and neck squamous cell carcinoma (LAHNSCC).
40. A retrospective analysis of the role of gefitinib in the definitive management of esophageal/gastroesophageal junction (E/GEJ) cancer.
41. Is there an interaction between epidermal growth factor receptor (EGFR) inhibition and p16-status in patients (pts) with oropharyngeal squamous cell cancer: A retrospective analysis.
42. Correlation between toxicity and outcome after multimodality therapy of locoregionally advanced (LRA) adenocarcinoma (ACA) of the esophagus (E) and gastroesophageal junction (GEJ).
43. Relationship between treatment duration and outcomes in patients receiving concurrent chemoradiotherapy (CCRT) and surgery for locoregionally advanced (LRA) esophageal and gastroesophageal junction (E/GEJ) adenocarcinoma (ACA).
44. Developing an In-Training Examination for Fellows: The Experience of the American Society of Clinical Oncology
45. Redefining the Role of Induction Chemotherapy in Head and Neck Cancer
46. American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer
47. Does Induction Chemotherapy Have a Role in the Management of Locoregionally Advanced Squamous Cell Head and Neck Cancer?
48. Multiagent Concurrent Chemoradiotherapy for Locoregionally Advanced Squamous Cell Head and Neck Cancer: Mature Results From a Single Institution
49. Induction Redux: Once More With Taxanes
50. Organ Preservation for Advanced Resectable Cancer of the Base of Tongue and Hypopharynx: A Southwest Oncology Group Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.